Showing 5591-5600 of 8845 results for "".
- LEO Pharma Receives EU Marketing Authorization for Kyntheum to Treat Plaque Psoriasishttps://practicaldermatology.com/news/leo-pharma-receives-eu-marketing-authorization-for-kyntheumfor-the-treatment-of-plaque-psoriasis/2458114/The European Commission has granted marketing authorisation for LEO Pharma's Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy. Kyntheum selectively targets the IL-17 recep
- Joseph H. Boccuzi Appointed to Allergan plc Board of Directorshttps://practicaldermatology.com/news/joseph-h-boccuzi-appointed-to-allergan-plc-board-of-directors/2458116/Allergan plc has named Joseph H. Boccuzi to its Board of Directors, effective immediately. Mr. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with
- Paratek: Phase 3 Study of Oral-Only Dosing of Omadacycline Met FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infectionshttps://practicaldermatology.com/news/paratek-phase-3-study-of-oral-only-dosing-of-omadacycline-met-fda-and-ema-efficacy-endpoints-in-acute-bacterial-skin-infections/2458118/Paratek Pharmaceuticals, Inc. shared positive top-line results from a pivotal Phase 3 study comparing its once-daily, oral investigational antibiotic, omadacycline, to twice-daily oral linezolid in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The study met all of
- Syneron Candela Completes Transaction with Funds Advised by Apax Partners; Becomes a Private Companyhttps://practicaldermatology.com/news/syneron-candela-completes-transaction-with-funds-advised-by-apax-partners-becomes-a-private-company/2458121/Syneron Medical Ltd. announced the successful completion of its acquisition by an affiliate of funds advised by Apax Partners for $11.00 per share in cash in a transaction valued at approximately $400 million. The transacti
- FDA Approves Janssen's Tremfya for Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-for-moderate-to-severe-plaque-psoriasis/2458123/The FDA has approved Janssen's Tremfya (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine that plays a
- Allergan CEO: Consensus Needed on Medical Aesthetic Treatment in Minorshttps://practicaldermatology.com/news/allergan-ceo-consensus-needed-on-medical-aesthetic-treatment-in-minors/2458125/Allergan Chairman & CEO Brent Saunders, the father of two high school-aged girls, is speaking up and out about the risks associated with offering medical aesthetic treatments to minors. In a new blog post, he writes “we must remember that anyone under the age of 18 is still matu
- Derms Urged to Step Up Role in Antibiotic Stewardshiphttps://practicaldermatology.com/news/derms-urged-to-step-up-role-in-antibiotic-stewardship/2458126/Dermatologists can and should play a larger role in antibiotic stewardship, according to researchers out of Perelman School of Medicine at the University of Pennsylvania in Philadelphia. Data from the CDC shows the average dermatology provider wrote 669 antibiotic prescriptions in 2014, t
- FOREO's New At-Home Blue Light Acne Pen Hits the US and Canadahttps://practicaldermatology.com/news/foreos-new-at-home-blue-light-acne-pen-hits-the-us-and-canada/2458129/FOREO's blue-light acne pen is now available in 333 stores in the US and Canada with more to be added by September 2017. The FOREO ESPADA comprises 415 nanometers (nm) of blue light energy combined with red cross-hair targeting that converges as ESP
- Array BioPharma Submits NDAs for Binimetinib and Encorafenib in Advanced Melanomahttps://practicaldermatology.com/news/array-biopharma-submits-ndas-for-binimetinib-and-encorafenib-in-advanced-melanoma/2458131/Array BioPharma submitted two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for the use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with&nbs
- Study: Soolantra is Both Anti-Inflammatory and Anti-Demodexhttps://practicaldermatology.com/news/study-soolantra-is-both-anti-inflammatory-and-anti-demodex/2458132/A recently published study sought to find scientific rationale for the dual anti-inflammatory and anti-parasitic mode of action of topical ivermectin 1% cream (Soolantra) in patients with rosacea. In a monocentric pilot study, 20 Caucasian patients with moderate to severe rosacea, as asse